ALPMY should take 4%ALPMY could grow and cross or at least touch the 20 days average around 13.25$
Would be a 4% growth
Next report date
Report period
Q1 2024
EPS estimate
0.06USD
Revenue estimate
2.66 BUSD
0.05USD
112.62 MUSD
10.60 BUSD
1.71 B
About ASTELLAS PHARMA
Sector
CEO
Naoki Okamura
Headquarters
Tokyo
Website
Founded
1923
ISIN
JP3942400007
FIGI
BBG000BVKB38
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ALPMF is 9.52 USD — it has decreased by 3.26% in the past 24 hours. Watch Astellas Pharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Astellas Pharma, Inc. stocks are traded under the ticker ALPMF.
Astellas Pharma, Inc. is going to release the next earnings report on Jul 30, 2024. Keep track of upcoming events with our Earnings Calendar.
ALPMF stock is 3.37% volatile and has beta coefficient of 0.71. Track Astellas Pharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Astellas Pharma, Inc. there?
ALPMF earnings for the last quarter are 0.07 USD per share, whereas the estimation was 0.12 USD resulting in a −37.98% surprise. The estimated earnings for the next quarter are −0.02 USD per share. See more details about Astellas Pharma, Inc. earnings.
Astellas Pharma, Inc. revenue for the last quarter amounts to 2.99 B USD despite the estimated figure of 2.74 B USD. In the next quarter revenue is expected to reach 2.51 B USD.
Yes, you can track Astellas Pharma, Inc. financials in yearly and quarterly reports right on TradingView.
ALPMF stock has fallen by 2.35% compared to the previous week, the month change is a 12.09% fall, over the last year Astellas Pharma, Inc. has showed a 35.89% decrease.
ALPMF net income for the last quarter is −219.87 M USD, while the quarter before that showed 102.85 M USD of net income which accounts for −313.77% change. Track more Astellas Pharma, Inc. financial stats to get the full picture.
Today Astellas Pharma, Inc. has the market capitalization of 18.16 B, it has decreased by 0.16% over the last week.
Astellas Pharma, Inc. dividend yield was 4.26% in 2023, and payout ratio reached 736.46%. The year before the numbers were 3.19% and 110.62% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, ALPMF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Astellas Pharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
ALPMF reached its all-time high on Mar 11, 2014 with the price of 63.15 USD, and its all-time low was 9.13 USD and was reached on Apr 16, 2024. View more price dynamics on ALPMF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Astellas Pharma, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Astellas Pharma, Inc. stock shows the strong sell signal. See more of Astellas Pharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Astellas Pharma, Inc. future price: according to them, ALPMF price has a max estimate of 14.89 USD and a min estimate of 7.77 USD. Watch ALPMF chart and read a more detailed Astellas Pharma, Inc. stock forecast: see what analysts think of Astellas Pharma, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Astellas Pharma, Inc. EBITDA is 2.22 B USD, and current EBITDA margin is 20.95%. See more stats in Astellas Pharma, Inc. financial statements.